One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD

Chest

Volumn 146, Issue 6, 2014, Pages 1531-1542

  Donohue, James F ^a   Hanania, Nicola A ^b   Make, Barry ^c   Miles, Matthew C ^d   Mahler, Donald A ^e   Curry, Lisa ^f   Tosiello, Robert ^f   Wheeler, Alistair ^f   Tashkin, Donald P ^g  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; PLACEBO; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION; ETHANOLAMINE DERIVATIVE; FORMOTEROL FUMARATE;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; BRAIN TUMOR; BRONCHITIS; CARDIOPULMONARY INSUFFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEAD INJURY; HEADACHE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SEPSIS; SINUSITIS; SQUAMOUS CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SAFETY; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; FORMOTEROL FUMARATE; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923372145     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0117     Document Type: Article

References (32)

1. 1 Global strategy for diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/ Accessed October 2, 2013.
2. 2 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152:5 pt 2 (1995), S77–S121.
3. 3 Pauwels, RA, Buist, AS, Ma, P, Jenkins, CR, Hurd, SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46:8 (2001), 798–825.
4. 4 Hanania, NA, Donohue, JF, Nelson, H, et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD 7:1 (2010), 17–31.
5. 5 Tuder, RM, Petrache, I, Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 122:8 (2012), 2749–2755.
6. 6 van den Boom, G, van Schayck, CP, van Möllen, MP, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 158:6 (1998), 1730–1738.
7. 7 Ingebrigtsen, TS, Marott, JL, Vestbo, J, et al. Characteristics of undertreatment in COPD in the general population. Chest 144:6 (2013), 1811–1818.
8. 8 Mathers, CD, Loncar, D, Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3(11), 2006, e442.
9. 9 Hurst, JR, Vestbo, J, Anzueto, A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:12 (2010), 1128–1138.
10. 10 Miravitlles, M, Mayordomo, C, Artés, M, Sánchez-Agudo, L, Nicolau, F, Segú, JL, Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med 93:3 (1999), 173–179.
11. 11 Seemungal, TA, Donaldson, GC, Paul, EA, Bestall, JC, Jeffries, DJ, Wedzicha, JA, Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:5 pt 1 (1998), 1418–1422.
12. 12 Halpin, DM, Decramer, M, Celli, B, Kesten, S, Liu, D, Tashkin, DP, Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 7 (2012), 653–661.
13. 13 Seymour, SM, Sullivan, EJ, Chowdhury, BA, Meyer, RJ, Davi, RC, Comments on the Salmeterol Multicenter Asthma Research Trial. Chest 130:3 (2006), 930–931.
14. 14 Chowdhury, BA, Dal Pan, G, The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 362:13 (2010), 1169–1171.
15. 15 Chowdhury, BA, Seymour, SM, Levenson, MS, Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 364:26 (2011), 2473–2475.
16. 16 Decramer, ML, Hanania, NA, Lötvall, JO, Yawn, BP, The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 8 (2013), 53–64.
17. 17 Kew, KM, Mavergames, C, Walters, JA, Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 10, 2013, CD010177.
18. 18 Feary, JR, Rodrigues, LC, Smith, CJ, Hubbard, RB, Gibson, JE, Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 65:11 (2010), 956–962.
19. 19 Calverley, PM, Anderson, JA, Celli, B, et al. TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 65:8 (2010), 719–725.
20. 20 Donohue, JF, Singh, D, Kornmann, O, Lawrence, D, Lassen, C, Kramer, B, Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 6 (2011), 477–492.
21. 21 Worth, H, Chung, KF, Felser, JM, Hu, H, Rueegg, P, Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 105:4 (2011), 571–579.
22. 22 Wilchesky, M, Ernst, P, Brophy, JM, Platt, RW, Suissa, S, Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 142:2 (2012), 305–311.
23. 23 Brovana (arformoterol tartrate) [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2011.
24. 24 Nelson, HS, Weiss, ST, Bleecker, ER, Yancey, SW, Dorinsky, PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:1 (2006), 15–26.
25. 25 Donohue, JF, Maleki-Yazdi, MR, Kilbride, S, Mehta, R, Kalberg, C, Church, A, Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 107:10 (2013), 1538–1546.
26. 26 Baumgartner, RA, Hanania, NA, Calhoun, WJ, Sahn, SA, Sciarappa, K, Hanrahan, JP, Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 29:2 (2007), 261–278.
27. 27 Cazzola, M, Hanania, NA, Matera, MG, Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med 4:2 (2010), 155–162.
28. 28 Donohue, JF, Hanania, NA, Sciarappa, KA, et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis 2:2 (2008), 37–48.
29. 29 Calverley, PM, Anderson, JA, Celli, B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:8 (2007), 775–789.
30. 30 Tashkin, DP, Celli, B, Senn, S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:15 (2008), 1543–1554.
31. 31 Welte, T, Miravitlles, M, Hernandez, P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180:8 (2009), 741–750.
32. 32 Rabe, KF, Treating COPD—the TORCH trial, P values, and the Dodo. N Engl J Med 356:8 (2007), 851–854.